immagine

Attività svolta

Desidero ricevere una copia cartacea
Informativa sulla privacy
Iscrizione alla newsletter

Speciale mastiti

Importanza della terapia antibiotica in corso di mastite severa da enterobatteriacee: analisi critica della bibliografia

Bibliografia

1. Anderson KL, Smith AR, Gustafsson K et coll. Diagnosis and treatment of acute mastitis in a large dairy herd. J. Am. Vet. Med. Assoc. 1982; 181: 690-693.

2. Cebra CK, Garry FB, Dinsmore RP. Naturally occuring acute coliform mastitis in Holstein cattle. J. Vet. Intern. Med. 1996; 10: 252-257.

3. Dosogne H, Meyer E, Sturk A et coll. Effect of enrofloxacin treatment on plasma endotoxin during bovine Escherichia coli mastitis. In_amm. Res. 2002; 51: 201-205.

4. Erskine RJ, Kirk JH, Tyler JW et coll. Advances in the therapy for mastitis. Vet. Clin. North Am. Food Anim. Pract. 1993; 9: 499- 517.

5. Erskine RJ, Barlett PC, VanLente JL et coll. E_cacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J. Dairy Sci. 2002; 85: 2571-2575.

6. Guterbock WM, Van Eenennaam AL, Anderson RJ et coll. Efficacy of intramammary antibiotic therapy for treatment of clinical mastitis caused by environmental pathogens. J. Dairy Sci. 1993; 76: 3437-3444.

7. Hoeben BD, Monfardini E, Burvenich C et coll. Treatment of acute Escherichia coli mastitis in cows with enrofloxacin: effect on clinical signs and chemiluminescence of circulating neutrophils. J. Dairy Res. 2000; 67: 485-502.

8. Hogan JS, Smith KL, Hoblet KH et coll. Field survey of mastitis in low somatic cell count herds. J. Dairy Sci. 1989; 72: 1547-1556.

9. Katholm J, Andersen P. Severe coliform mastitis in practice: Efficacy of the therapy regimen not including antibiotics. Proc. XX World Buiatrics Congress, Sydney, Australia. 1998: 261-264.

10. Lohuis JACM, Van Leeuwen W, Verheeijden JHM et colll. Flunixin meglumine and furbiprofen in cows with experimental Escherichia coli mastitis. Vet. Rec. 1989; 124: 305-308.

11. Menzies FD, Mc Bride SH, Mc Dowell SW et coll. Clinical and laboratory _ndings in cases of toxic mastitis in cows in Northern Ireland. Vet. Rec. 2000; 147: 123-128.

12. Morin DE, Shanks RD, McCoy GC. Comparison of antibiotic administration in conjunction with supportive measures versus supportive measures alone for treatment of dairy cows with clinical mastitis. J. Am. Vet. Med. Assoc. 1998; 213: 676-684.

13. Oliveira L, Ruegg PL. Treatments for clinical mastitis and other diseases in large dairy herds in Wisconsin. J. Dairy Sci. 2011; 94: 66.

14. Persson Y, Katholm J, Landin H et coll. Efficacy of enrofloxacin for the treatment of acute clinical mastitis caused by Escherichia coli in dairy cows. Vet. Rec. 2015; 76 (26): 673.

15. Pinzon-Sanchez C, Ruegg PL. Risk factors associated with short-term post-treatment outcome of clinical mastitis. J. Dairy Sci. 2011; 94: 3397-3410.

16. Poutrel B, Stegemann MR, Roy O et coll. Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acute Escherichia coli bovine mastitis. J. Dairy Res. 2008; 75: 310-318.

17. Poutrel B. Les mammites colibacillaires chez les vaches laitières. Bull. GTV. 2010; 54: 17-26.

18. Pyörälä S, Kaartinen L, Käck H et coll. Efficacy of two therapy regimens for treatment of experimentally induced Escherichia coli mastitis in cows. J. Dairy Sci. 1994; 77: 453-461. 1

19. Rantala M, _Kaartinen L, Välimäki ed et coll. E_cacy and pharmacokinetics of enrofloxacin and flunixin meglumine for treatment of cows with experimentally induced Escherichia coli mastitis. J. Vet. Pharmacol. Ther. 2002; 25: 251-258.

20. Rodrigues ACO, Ruegg PL. Actions and outcomes of Wisconsin dairy herds completing milk quality teams. J. Dairy Sci. 2005; 88: 2672-2680.

21. Salat O, Lemaire G, Perrot F. Ètiologie des mammites en fonction de la sévérité clinique et conséquences pour le traitement. Nouv. Prat. 2016; 35: 23-32.

22. Schukken YH, Zurakowski MJ, Rauch BJ et coll. Non inferiority trial comparing a first-generation cephalosporin with a thirdgeneration cephalosporin in the treatment of non severe clinical mastitis in dairy cows. J. Dairy Sci. 2013; 96: 6763-6774.

23. Smith KL, Todhunter DA, Schoenberger PS. Environnemental mastitis: cause, prevalence, prevention. J. Dairy Sci. 1985; 68: 1531-1553.

24. Shpigel NY, Levin D, Winkler M et coll. E_cacy of cefquinome for treatment of cows with mastitis experimentally induced using Escherichia coli. J. Dairy Sci. 1997; 80: 318-323.

25. Shpigel NY, Winkler M, Ziv G et coll. Relationship between in vitro sensitivity of coliform pathogens in the udder and the outcome of treatment for clinical mastitis. Vet. Rec. 1998; 142: 135-137.

26. Suojala L, Simojoki H, Mustonen K et coll. E_cacy of enro_oxacin in the treatment of naturally occurring acute clinical Escherichia coli mastitis. J. Dairy Sci. 2010; 93: 1960-1969.

27. Suojala L, Kaartinen L, Pyörälä S. Treatment for bovine Escherichia coli mastitis - an evidence-based approach. J. Vet. Pharmacol. Ther. 2013; 36: 521- 531.

28. Thomas E, Grandemange E, Davot JL et coll. Efficacité de Marbocyl 10% dans le traitement des mammites aiguës à bactéries Gram négatives des vaches laitières: résultats d’un essai terrain. Dans: Espinasse J. e. Le nouveau péripartum. Société française de Buiatrie, Paris. 1998: 300.

29. Wenz JR, Barrington GM, Garry FB et coll. Bacteriemia associated with naturally occurring acute coliform mastitis in dairy cows. J. Am. Vet. Med. Assoc. 2001; 219: 976-981.

30. Wenz JR, Fox LK, Muller FJ et coll. Factors associated with concentrations of select cytokine and acute phase proteins in dairy cows with naturally occurring clinical mastitis. J. Dairy Sci. 2010; 93: 2458-2470.

 

TORNA INDIETRO
Abbonati per accedere

Dal web internazionale
30/05/2019

Reti antimosca nella prevenzione della trasmissione del virus della leucemia bv

Il virus della leucemia bovina viene trasmesso a livello di mandria per via orizzontale attraverso sangue infetto. Un studio giapponese di campo sviluppato durante l’arco di tre anni (2013-2016) ha voluto confermare quale potenziale fattore di rischio di trasmissione del virus della leucemia bovina la presenza stabile di mosche succhiasangue e determinare l’efficacia del controllo dei vettori della patologia nella prevenzione della trasmissione del VLB.

 
 

Formazione a distanza abbinata a SUMMA

 

 

Formazione Settore Agro-Zootecnico